Where is Henlix located?

Henlix is headquartered in Neihu, Taiwan.

Who is the current CEO of Henlix?

Scott Liu of Henlix. They have also founded 1 company.

Is Henlix a funded company?

Henlix is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Henlix rank among its competitors?

Henlix ranks 3083rd amongst 3227 active competitors, of which 1114 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Henlix?

Henlix's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Henlix - 2026 Company Profile, Team, Funding & Competitors

Company Details

HENLIX develops monoclonal antibody-based drugs. The company helps in the discovery and development of innovative monoclonal antibody therapeutics, bi-specific antibodies and antibody-drug conjugates (ADCs). The main focus of the company is to treat lung cancer and solid tumors. The products are in the preclinical phase.

Website: henlix.com
Email ID: *****@henlix.com
Phone Number: +886 **********

Key Metrics

Founded Year

2010

Location

Neihu, Taiwan

Stage

Deadpooled

Investors

TF Capital & 1 more

Ranked

3083^rd among 3227 active competitors

Similar Companies

Jazz Pharmaceuticals & 2967 more

View Henlix's full profile

Henlix is a funded company. Henlix has 2 institutional investors.

View details of Henlix's funding rounds and investors

The founders of Henlix is Scott Liu. Scott Liu is the CEO of Henlix.

Here are the details of Henlix's key team members:

Scott Liu: Co-Founder & CEO of Henlix.

View details of Henlix's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Henlix include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Henlix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
3083rd	Henlix 2010, Neihu (Taiwan), Deadpooled	Developer of monoclonal antibody-based drugs	-	TF Capital, Hermed Capital	19/100